Clinical Trials
44 trials18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Peking University Cancer Hospital & Institute
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial
Thomas Jefferson University
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Alliance for Clinical Trials in Oncology
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
Jonsson Comprehensive Cancer Center
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Lung Nodule Detection Using Ultra-long FOV PET/CT
University Medical Center Groningen
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
University of Washington
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
Peking Union Medical College Hospital
Clinical Study of 18F-Alfatide Injection PET/CT
Yantai LNC Biotechnology Singapore PTE. LTD.
Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy
Emory University
Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
Eastern Cooperative Oncology Group
Multimodalitic Imaging in the N-stage of Lung Cancer
Peking University First Hospital
PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor
Peking University Cancer Hospital & Institute
18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules
Vanderbilt-Ingram Cancer Center
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Stanford University
PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
18F-FSPG PET/CT for Cancer Patients on Therapy
Stanford University
ACRIN6678
American College of Radiology Imaging Network
Sunitinib Malate in Treating Patients With Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung Cancer
Ohio State University Comprehensive Cancer Center
Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
Boston Medical Center
Fludeoxyglucose F 18 in Detecting Lymph Node Metastasis in Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed by Surgery
Roswell Park Cancer Institute
Positron Emission Tomography and Computed Tomography in Planning Treatment for Patients Undergoing 3-Dimensional Conformal Radiation Therapy for Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery. ICORG 06-35
Cancer Trials Ireland
Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
University of Washington
A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
Genentech, Inc.
A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC
National Cancer Institute (NCI)
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
University of Washington
Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer
Virginia Commonwealth University
18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study
Shanghai Chest Hospital
Positron Emission Tomography for Detecting Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT
Xijing Hospital
Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer
National Cancer Institute (NCI)
Pharmacokinetic and Radiation Dosimetry Study Evaluating 99m TC-EC-DG SPECT/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
Cell>Point LLC
Phase 2 Study Comparing 99mTc-EC-DG SPECT/CT With 18F FDG PET/CT in Patients With Non-small Cell Lung Cancer (NSCLC)
Cell>Point LLC
PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery
Memorial Sloan Kettering Cancer Center
Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
Abramson Cancer Center at Penn Medicine
Fludeoxyglucose F 18 PET/CT Scans in Predicting Therapy Response in Patients With Stage IIIA Non-Small Cell Lung Cancer Undergoing Chemoradiation
City of Hope Medical Center
11C Topotecan PET Imaging
Case Comprehensive Cancer Center
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
FDG-PET lung
Maastricht Radiation Oncology